

## Disclosures

### Personal Commercial (17)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amarin	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention General Cardiology</i>
Amgen Inc.	Speaker's Bureau	Modest (< \$5,000)	<i>General Cardiology</i>
AstraZeneca	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology</i>
Bayer	Research/Research Grants ‡ COMPASS	Significant (>= \$5,000)	<i>General Cardiology</i>
Bayer	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
BMS	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Boehringer-Ingelheim	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP</i>
IDORSIA	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Acute Coronary Syndromes</i>
Merck & Co., Inc.	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Novartis	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Novo Nordisk	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
Pfizer Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
PhaseBio	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Acute Coronary Syndromes</i>
Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
sanofi-aventis	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology</i>
Sanofi-Aventis	Research/Research Grants	Modest (< \$5,000)	<i>General Cardiology</i>
Servier	Research/Research Grants ‡ CLARIFY	Significant (>= \$5,000)	<i>General Cardiology</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American Heart Association ‡ none	Other - Senior Associate Editor - Circulation	Significant (>= \$5,000)	<i>Acute Coronary Syndromes</i>

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 10/11/2023

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/11/2023

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 10/11/2023

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 10/11/2023

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.